Literature DB >> 7634386

Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

D C Thompson1, A Vaisman, M K Sakata, S D Wyrick, D J Holbrook, S G Chaney.   

Abstract

We examined the intracellular biotransformation products of ormaplatin [(d,l-trans)1,2-diaminocyclohexanetetrachloroplatinum(IV)] (formerly called tetraplatin) in liver, kidney, spleen, small intestine, and plasma of the adult male Fischer 344 rat. Previous studies have established that the rank order of ormaplatin toxicity in Fischer 344 rats is spleen approximately gastrointestinal tract > kidney >> liver. Animals were given tritium-labelled drug i.v. at 12.5 mg/kg, and tissues were harvested 30 min later. The kidney was found to concentrate total and cytosolic platinum to a greater extent than any of the other tissues. The absolute amount of cytosolic platinum, in micrograms per gram tissue, that was irreversibly bound to protein and/or other macromolecules was also greatest in the kidney. However, when the amount bound was expressed as a percentage of the total cytosolic platinum, the kidney was significantly lower than any other tissue. Of the various low molecular mass platinum biotransformation species characterized, by far the most abundant were complexes of platinum with the sulfur-containing molecules cysteine, methionine, and glutathione (GSH). There was more of the methionine complex in the blood plasma than in any of the tissues except for the spleen. No significant differences among the tissues were detected for the dichloro, cysteine, methionine, or the GSH complexes. The tritium-labelled diaminocyclohexane (DACH) carrier ligand appeared to remain stably bound to the platinum while in the plasma, as there was less free DACH ligand detected in plasma ultrafiltrate than in any tissue ultrafiltrate. Among the tissues, the free DACH levels were in the range of 20% of the radioactivity recovered from the HPLC column and were not significantly different. Consequently, neither biodistribution nor tissue-specific biotransformation of ormaplatin provides a ready explanation for the tissue specificity of ormaplatin toxicity in Fischer 344 rats. However, in kidney there was much less of the reactive PtCl2(DACH) species than has previously been reported for the corresponding Pt(NH3)2Cl2 species in cisplatin-treated rats. Thus, these data suggest a possible explanation for differences in nephrotoxicity induced by cisplatin versus that by ormaplatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634386     DOI: 10.1007/bf00686194

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

1.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Antitumor activity of platinum complexes.

Authors:  J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

4.  High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand.

Authors:  S K Mauldin; F A Richard; M Plescia; S D Wyrick; A Sancar; S G Chaney
Journal:  Anal Biochem       Date:  1986-08-15       Impact factor: 3.365

5.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

Review 6.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

7.  Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats.

Authors:  P F Carfagna; S D Wyrick; D J Holbrook; S G Chaney
Journal:  J Biochem Toxicol       Date:  1991

8.  Relative lack of toxicity of transplatin compared with cisplatin in rodents.

Authors:  K S Blisard; D A Harrington; D A Long; J E Jackson
Journal:  J Comp Pathol       Date:  1991-11       Impact factor: 1.311

9.  An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

Authors:  S G Chaney; G R Gibbons; S D Wyrick; P Podhasky
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

10.  Apparent rates of glutathione turnover in rat tissues.

Authors:  D W Potter; T B Tran
Journal:  Toxicol Appl Pharmacol       Date:  1993-06       Impact factor: 4.219

View more
  1 in total

Review 1.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.